Therapies for Children With Autism Spectrum Disorders

Evidence Table. Therapies for children with ASD (continued)
Study
Inclusion/ Exclusion
Description Intervention
Criteria/ Population
study, on language, social NR
interaction and behavioral Diagnostic category:
problems, as well as NR
motor functioning; Other characteristics:
quantitative electroencephalogram
(qEEG)
Groups:
G1: needle stimulation
G2: waitlist control
Co-interventions held
stable during treatment:
NR
Frequency of contact
during study:
5 days a week for 6
weeks, assessed at
baseline and 6 weeks
after treatment
Concomitant therapies
NR
N at enrollment:
G1: 16
G2: 16
N at follow-up:
G1: 16
G2: 16
NR
Chan et al., 2009
(continued)
Author:
Correia et al.,
2009
Country:
Intervention:
Inclusion criteria:
Risperidone administered • Met the algorithm cut-
with progressive
off for the ADI-R and
increments each 2 weeks, ADOS
C-38
Baseline
Measures
G2: 178.20 ± 38.81
Outcomes
(n=9)
Sensory:
Theta:
QEEG spectral
G1: 107.71 ± 31.90 amplitude, mean ±
(n=7)
SD:
G2: 78.73 ± 16.90 Delta:
(n=9)
G1: 165.77 ± 81.61
Alpha:
(n=7)
G1: 61.86 ± 26.66 G2: 197.34 ± 51.35
(n=7)
(n=9)
G2: 45.62 ± 12.21 ANOVA: treatment
(n=9)
x time (P < 0.05)
Beta:
G1/G2: P < 0.05
G1: 33.71 ± 17.16 Theta:
(n=7)
G1: 70.50 ± 15.62
G2: 20.20 ± 4.60 (n=7)
(n=9)
G2: 73.80 ± 12.21
High beta: (n=9)
G1: 34.23 ± 18.51 ANOVA: treatment
(n=7)
x time (P < 0.05)
G2: 24.19 ± 3.68
(n=9)
G1/G2: P < 0.05
Autism Treatment
Evaluation
Checklist (ATEC),
mean ± SD.:
Alpha:
G1: 49.89 ± 13.44
(n=7)
G2: 43.36 ± 6.35
(n=9)
ANOVA: treatment
(P < 0.05), time x
treatment (P = NS)
G1/G2: P = NS
Beta:
G1: 26.61 ± 13.82
(n=7)
G2: 28.93 ± 9.68
(n=9)
ANOVA: treatment
x time (P < 0.05)
G1/G2: P < 0.05
High beta:
G1: 18.76 ± 7.58
G2: 29.54 ± 13.47
ANOVA: treatment
x time (P < 0.05)
G1/G2: P < 0.05
Harms:
NR
Modifiers:
NR
Overall ratings:
ATEC total, mean
± SD:
34.71 ± 23.63